{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T12:59:31Z","timestamp":1775134771153,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Guangdong Provincial Science and Technology Planning Project","award":["Grant No. 2023B110009"],"award-info":[{"award-number":["Grant No. 2023B110009"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-026-04362-7","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T11:56:57Z","timestamp":1775131017000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immune checkpoint inhibitor\u2013related myocarditis in patients with thymic epithelial tumors: a retrospective cohort analysis"],"prefix":"10.1007","volume":"75","author":[{"given":"Haiyan","family":"Zeng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sijia","family":"Pu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junrong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanlin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiyi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengmeng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Yi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haowei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenzhao","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumei","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"issue":"6","key":"4362_CR1","doi-asserted-by":"publisher","first-page":"255","DOI":"10.6004\/jnccn.2025.0027","volume":"23","author":"GJ Riely","year":"2025","unstructured":"Riely GJ, Wood DE, Loo BW Jr, Aisner DL, Akerley W, Bauman JR et al (2025) Thymomas and thymic carcinomas, Version 2.2025, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 23(6):255\u2013269. https:\/\/doi.org\/10.6004\/jnccn.2025.0027","journal-title":"J Natl Compr Canc Netw"},{"issue":"8","key":"4362_CR2","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","volume":"186","author":"P Sharma","year":"2023","unstructured":"Sharma P, Goswami S, Raychaudhuri D et al (2023) Immune checkpoint therapy-current perspectives and future directions. Cell 186(8):1652\u20131669. https:\/\/doi.org\/10.1016\/j.cell.2023.03.006","journal-title":"Cell"},{"issue":"9","key":"4362_CR3","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.3390\/cancers14092060","volume":"14","author":"M Ballman","year":"2022","unstructured":"Ballman M, Zhao C, McAdams MJ, Rajan A (2022) Immunotherapy for management of thymic epithelial tumors: a double-edged sword. Cancers (Basel) 14(9):2060. https:\/\/doi.org\/10.3390\/cancers14092060","journal-title":"Cancers (Basel)"},{"key":"4362_CR4","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ejca.2022.12.005","volume":"180","author":"J Remon","year":"2023","unstructured":"Remon J, Villacampa G, Facchinetti F, Di Maio M, Marcuse F, Tiseo M et al (2023) Immune checkpoint blockers in patients with unresectable or metastatic thymic epithelial tumours: a meta-analysis. Eur J Cancer 180:117\u2013124. https:\/\/doi.org\/10.1016\/j.ejca.2022.12.005","journal-title":"Eur J Cancer"},{"issue":"25","key":"4362_CR5","doi-asserted-by":"publisher","first-page":"02940","DOI":"10.1016\/j.jtho.2025.12.002","volume":"S1556\u20130864","author":"IN Agmon","year":"2025","unstructured":"Agmon IN, Zhan LJ, Ho G, Foroutan F, Power C, Bezjak A et al (2025) The risk of cardiovascular adverse outcomes in patients with thymoma or thymic carcinoma receiving cancer therapy. J Thorac Oncol S1556\u20130864(25):02940\u201302945. https:\/\/doi.org\/10.1016\/j.jtho.2025.12.002","journal-title":"J Thorac Oncol"},{"issue":"12","key":"4362_CR6","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1038\/s41591-023-02591-2","volume":"29","author":"C Fenioux","year":"2023","unstructured":"Fenioux C, Abbar B, Boussouar S, Bretagne M, Power JR, Moslehi JJ et al (2023) Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis. Nat Med 29(12):3100\u20133110. https:\/\/doi.org\/10.1038\/s41591-023-02591-2","journal-title":"Nat Med"},{"issue":"2","key":"4362_CR7","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.21037\/tcr-23-2212","volume":"13","author":"Y Feng","year":"2024","unstructured":"Feng Y, Zheng P, Zhang W, Yang S, You Y, Chen Y et al (2024) Immune checkpoint inhibitor myocarditis in thymic epithelial tumors: a case report and literature review. Transl Cancer Res 13(2):1208\u20131218. https:\/\/doi.org\/10.21037\/tcr-23-2212","journal-title":"Transl Cancer Res"},{"key":"4362_CR8","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac244","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS et al (2022) 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. https:\/\/doi.org\/10.1093\/eurheartj\/ehac244","journal-title":"Eur Heart J"},{"key":"4362_CR9","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD et al (2021) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol 39:4073\u20134126. https:\/\/doi.org\/10.1200\/JCO.21.01440","journal-title":"J Clin Oncol"},{"issue":"19","key":"4362_CR10","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","volume":"385","author":"LA Inker","year":"2021","unstructured":"Inker LA, Eneanya ND, Coresh J et al (2021) New Creatinine\u2010 and Cystatin C\u2010based equations to estimate GFR without Race. N Engl J Med 385(19):1737\u20131749. https:\/\/doi.org\/10.1056\/NEJMoa2102953","journal-title":"N Engl J Med"},{"issue":"10124","key":"4362_CR11","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","volume":"391","author":"JJ Moslehi","year":"2018","unstructured":"Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB (2018) Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet 391(10124):933. https:\/\/doi.org\/10.1016\/S0140-6736(18)30533-6","journal-title":"Lancet"},{"key":"4362_CR12","doi-asserted-by":"publisher","first-page":"746304","DOI":"10.3389\/fonc.2021.746304","volume":"11","author":"XT Yu","year":"2021","unstructured":"Yu XT, Yu L, Du X, Yu Z, Yang XG, Jiang YX (2021) Clinical and genetic characteristics of thymoma patients with autoimmune hepatitis and myocarditis. Front Oncol 11:746304. https:\/\/doi.org\/10.3389\/fonc.2021.746304","journal-title":"Front Oncol"},{"key":"4362_CR13","doi-asserted-by":"publisher","first-page":"35","DOI":"10.21037\/med.2019.08.02","volume":"3","author":"C Zhao","year":"2019","unstructured":"Zhao C, Rajan A (2019) Immune checkpoint inhibitors for treatment of thymic epithelial tumors, how to maximize benefit and optimize risk? Mediastinum 3:35. https:\/\/doi.org\/10.21037\/med.2019.08.02","journal-title":"Mediastinum"},{"key":"4362_CR14","doi-asserted-by":"publisher","first-page":"114191","DOI":"10.1016\/j.ejca.2024.114191","volume":"207","author":"AC Toublanc","year":"2024","unstructured":"Toublanc AC, Faure M, Verdy G et al (2024) Prospective cardiovascular events in patients with advanced thoracic cancer treated with immune checkpoint inhibitor. Eur J Cancer 207:114191. https:\/\/doi.org\/10.1016\/j.ejca.2024.114191","journal-title":"Eur J Cancer"},{"issue":"5","key":"4362_CR15","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.jaccao.2020.10.013","volume":"2","author":"S Liu","year":"2020","unstructured":"Liu S, Chan J, Brinc D et al (2020) Immune checkpoint inhibitor-associated myocarditis with persistent troponin elevation despite abatacept and prolonged immunosuppression. JACC CardioOncol 2(5):800\u2013804. https:\/\/doi.org\/10.1016\/j.jaccao.2020.10.013","journal-title":"JACC CardioOncol"},{"issue":"2","key":"4362_CR16","doi-asserted-by":"publisher","first-page":"360","DOI":"10.21037\/tlcr.2020.02.05","volume":"9","author":"G Lie","year":"2020","unstructured":"Lie G, Weickhardt A, Kearney L et al (2020) Nivolumab resulting in persistently elevated troponin levels despite clinical remission of myocarditis and myositis in a patient with malignant pleural mesothelioma, case report. Transl Lung Cancer Res 9(2):360\u2013365. https:\/\/doi.org\/10.21037\/tlcr.2020.02.05","journal-title":"Transl Lung Cancer Res"},{"issue":"48","key":"4362_CR17","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.1093\/eurheartj\/ehz766","volume":"40","author":"KM Sturgeon","year":"2019","unstructured":"Sturgeon KM, Deng L, Bluethmann SM et al (2019) A population-based study of cardiovascular disease mortality risk in US cancer patients. Eur Heart J 40(48):3889\u20133897. https:\/\/doi.org\/10.1093\/eurheartj\/ehz766","journal-title":"Eur Heart J"},{"issue":"5","key":"4362_CR18","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.jaccao.2022.11.004","volume":"4","author":"A Vasbinder","year":"2022","unstructured":"Vasbinder A, Chen Y, Procureur A et al (2022) Biomarker trends, incidence, and outcomes of immune checkpoint inhibitor-induced myocarditis. JACC CardioOnc 4(5):689\u2013700. https:\/\/doi.org\/10.1016\/j.jaccao.2022.11.004","journal-title":"JACC CardioOnc"},{"issue":"3","key":"4362_CR19","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/cmi.2010.74","volume":"8","author":"S Shelly","year":"2011","unstructured":"Shelly S, Agmon-Levin N, Altman A, Shoenfeld Y (2011) Thymoma and autoimmunity. Cell Mol Immunol 8(3):199\u2013202. https:\/\/doi.org\/10.1038\/cmi.2010.74","journal-title":"Cell Mol Immunol"},{"issue":"5","key":"4362_CR20","doi-asserted-by":"publisher","first-page":"189145","DOI":"10.1016\/j.bbcan.2024.189145","volume":"1879","author":"Y Yang","year":"2024","unstructured":"Yang Y, Yu Y, Fan Y, Li H (2024) Evolving treatment landscape in thymic epithelial tumors: from mechanism to therapy. Biochim Biophys Acta Rev Cancer 1879(5):189145. https:\/\/doi.org\/10.1016\/j.bbcan.2024.189145","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"6","key":"4362_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111611","volume":"41","author":"T Won","year":"2022","unstructured":"Won T, Kalinoski HM, Wood MK, Hughes DM, Jaime CM, Delgado P et al (2022) Cardiac myosin-specific autoimmune T-cells contribute to immune-checkpoint-inhibitor-associated myocarditis. Cell Rep 41(6):111611. https:\/\/doi.org\/10.1016\/j.celrep.2022.111611","journal-title":"Cell Rep"},{"issue":"1","key":"4362_CR22","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12943-023-01772-4","volume":"22","author":"YQ Ao","year":"2023","unstructured":"Ao YQ, Gao J, Wang S, Jiang JH, Deng J, Wang HK et al (2023) Immunotherapy of thymic epithelial tumors: molecular understandings and clinical perspectives. Mol Cancer 22(1):70. https:\/\/doi.org\/10.1186\/s12943-023-01772-4","journal-title":"Mol Cancer"},{"issue":"7937","key":"4362_CR23","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/s41586-022-05432-3","volume":"611","author":"ML Axelrod","year":"2022","unstructured":"Axelrod ML, Meijers WC, Screever EM, Qin J, Carroll MG, Sun X et al (2022) T-cells specific for \u03b1-myosin drive immunotherapy-related myocarditis. Nature 611(7937):818\u2013826. https:\/\/doi.org\/10.1038\/s41586-022-05432-3","journal-title":"Nature"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04362-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-026-04362-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04362-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T11:56:58Z","timestamp":1775131018000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-026-04362-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":23,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["4362"],"URL":"https:\/\/doi.org\/10.1007\/s00262-026-04362-7","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,2]]},"assertion":[{"value":"27 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study was approved by the Guangdong Provincial People\u2019s Hospital Ethics Committee (KY2024-1057\u201302) and was performed according to the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"132"}}